ReviewThe Journal of international medical research2025
Primary squamous cell carcinoma of the pancreas with treatment-refractory characteristics: A case report and literature review.
Review in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary pancreatic squamous cell carcinoma with duodenal invasion: Literature review and a case report.Radiology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma of the pancreas is sporadic and rarely reported. This uncommon disease is characterized by rapid proliferation, high aggressiveness, and poor prognosis. To date, no standard treatment regimen has been established for this malignancy. The present study reported on a patient diagnosed with primary squamous cell carcinoma of the pancreas who showed recurrence after radical resection and adjuvant chemotherapy. The patient was refractory to salvage therapy with cytotoxic drugs, anti-angiogenesis drugs, and even immune checkpoint inhibitors, resulting in a poor prognosis. Notably, the Ki-67 proliferation index, a marker of tumor cell proliferation, increased from 40% in the surgical specimen to 80% in the recurrent tumor within 2 months. In addition, the literature on clinical characteristics as well as treatment options and their efficacy in patients with squamous cell carcinoma of the pancreas was reviewed and summarized to improve the understanding of the disease and treatment choices. This case report offers valuable insights into squamous cell carcinoma of the pancreas progression and underscores the need for further research on this aggressive malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.